About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? [email protected]

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Changes in Pituitary Iron and Volume With Deferasirox

NCT01376622·1 site·ClinicalTrials.gov

What this study is about

Take this into the appointment.

Saves the questions and what to expect into your notes, next to the visit they belong to.

Keep this study

Lead

Children's Hospital Los Angeles

With

Novartis Pharmaceuticals

Age

2–25

Sex

ALL

Healthy volunteers

Accepted

You may be eligible if

Currently on chronic transfusion therapy.
Duration of chronic transfusion \>1 year.
Age 2 to 25 years
On deferasirox monotherapy for the duration of the study.
Informed consent from legal guardian and/or patient.
On deferasirox for a minimum of 3 months at start of study.

You may not be if

Sickle cell disease or sickle-beta zero genotype.
Combination of deferasirox and another iron chelator.

The record

StatusCompleted

PhaseNo phase

Taking part130

StartedNov 2008

UpdatedOct 31, 2023

Conditions

Where1

Children's Hospital Los Angeles
Los Angeles, California, United States

Clareo Health | Changes in Pituitary Iron and Volume With Deferasirox